NEWTON, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report fourth quarter and year-end 2025 financial results on Thursday, March 26, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business ...

Acumen Pharmaceuticals Conference Call Summary Company Overview - **Company**: Acumen Pharmaceuticals (NasdaqGS:ABOS) - **Focus**: Biotech company developing treatments for Alzheimer's disease - **Lead Program**: Sabirnetug, a humanized IgG2 monoclonal antibody targeting toxic soluble Abeta oligomers [1][2] Key Points Clinical Development - **Phase 2 Study**: ALTITUDE-AD, comparing two active doses of sabirnetug against placebo, with primary outcomes expected in late 2026 [3][4] - **Efficacy Goals**: Targeting an efficacy measure of 30% or better, ideally closer to 40%, at the 18-month endpoint [4][5] - **Safety Benchmark**: Aiming for an ARIA (Amyloid-related imaging abnormalities) rate of 10%-12%, which is comparable to current approved agents [5] Study Design - **Dosing Strategy**: Two doses selected for phase 2 based on phase 1 data, with a focus on plaque reduction and oligomer effects [8][10] - **Phase 1 Results**: High-dose cohorts showed plaque reduction of 21%-22% [9] - **Biomarker Analysis**: Phase 1 included pharmacodynamic assays to measure target engagement and effects on biomarkers [12][13] Scientific Rationale - **Oligomer Hypothesis**: Sabirnetug is designed to preferentially target toxic Abeta oligomers, which are believed to be neurotoxic [17][18] - **Differentiation from Competitors**: Emphasizes lower monomer binding potential compared to other antibodies, which may lead to better efficacy [22][23] Future Directions - **Subcutaneous (subQ) Development**: Awaiting ALTITUDE-AD results to inform next steps for subQ formulation [26][28] - **Collaboration with JCR Pharmaceuticals**: Focus on enhanced brain delivery mechanisms, with promising non-human primate study results showing significant improvements in brain concentrations [44][48] - **Timeline for IND**: Aiming for mid-2027 to enter clinical trials for enhanced delivery candidates [55] Market Position and Strategy - **Execution and Innovation**: Acumen emphasizes its commitment to innovation and efficient execution in the Alzheimer's space, with a dedicated team [36] - **Potential for Partnerships**: Open to collaboration for further development based on ALTITUDE-AD outcomes, considering the high costs of large-scale studies [58][59] Additional Insights - **Regulatory Considerations**: The study is being conducted as a registration-quality study, indicating a focus on meeting regulatory standards [36] - **Primary Endpoint**: iADRS chosen as the primary endpoint due to its sensitivity in early Alzheimer's populations, with CDR Sum of Boxes as a key secondary endpoint [37] This summary encapsulates the critical aspects of Acumen Pharmaceuticals' conference call, highlighting the company's strategic focus, clinical development plans, and scientific rationale behind its lead program.

Core Insights - Acumen Pharmaceuticals is advancing its Alzheimer's disease treatment, sabirnetug (ACU193), through innovative approaches targeting soluble amyloid beta oligomers (AβOs) [1][10] Group 1: Research Findings - New research findings were presented at the International Conference on Alzheimer's and Parkinson's Diseases, focusing on enhanced brain delivery methods, novel biomarker approaches, and selective antibody development [1][2] - The company is collaborating with JCR Pharmaceuticals to improve drug penetration across the blood-brain barrier using bispecific antibodies targeting transferrin receptors [3][11] - The Phase 1 INTERCEPT-AD study showed treatment-related biomarker changes, indicating sabirnetug's effects on key Alzheimer's biomarkers [4] Group 2: Enhanced Brain Delivery - Acumen's Enhanced Brain Delivery (EBD™) technology demonstrated increased brain exposure of sabirnetug while maintaining target engagement with AβOs [3][4] - The collaboration with JCR Pharmaceuticals utilizes the J-Brain Cargo® platform to facilitate brain uptake of therapeutics [3][11] Group 3: Biomarker Evaluation - The NULISAseq™ technology was employed to measure 127 proteins related to Alzheimer's pathology, showing strong correlations with established clinical platforms [4] - A dedicated bioanalytical database has been established to support further exploratory analyses and integration with ongoing studies [4] Group 4: Antibody Development - Acumen is developing highly selective anti-AβO antibodies, with ACU234 showing approximately 21,000-fold greater affinity for oligomers compared to monomers [5][6] - Further evaluation of ACU234 confirmed its ability to bind disease-relevant AβOs in both human brain samples and transgenic mouse models [6] Group 5: Clinical Trials - The ongoing Phase 2 ALTITUDE-AD study aims to evaluate the efficacy and safety of sabirnetug in slowing cognitive decline in early Alzheimer's patients, with 542 individuals enrolled [9] - Topline results from the ALTITUDE-AD study are expected in late 2026 [9]

Core Viewpoint - Acumen Pharmaceuticals has secured a private placement of approximately $35.75 million to support its Enhanced Brain Delivery program for Alzheimer's disease treatment, reflecting strong investor confidence in its therapeutic approach targeting amyloid beta oligomers [1][2][3] Financing Details - The private placement involves the sale of shares at a price of $3.30 per share, with expected gross proceeds of around $35.75 million before expenses [1] - The transaction was led by RA Capital Management and included participation from other institutional investors [2] - The closing of the private placement is anticipated on or about March 16, 2026, pending customary closing conditions [3] Use of Proceeds - Proceeds from the financing will primarily support the Enhanced Brain Delivery (EBD) program, including preclinical development and working capital [3] - An Investigational New Drug (IND) submission for a lead clinical candidate is targeted for mid-2027 [3] Enhanced Brain Delivery Program - Acumen's EBD program utilizes JCR Pharmaceuticals' J-Brain Cargo technology to enhance drug delivery across the blood-brain barrier [9] - Preclinical data indicate that development candidates achieved 14-40 times higher brain levels in non-human primates compared to native antibodies, with low anemia risk and favorable stability profiles [7][8][10] - The program aims to develop a potential best-in-class treatment for Alzheimer's disease by combining amyloid beta oligomer-targeting antibodies with transferrin-receptor-targeting technology [10] Company Background - Acumen Pharmaceuticals is focused on developing therapeutics targeting toxic soluble amyloid beta oligomers for Alzheimer's disease, with its lead candidate, sabirnetug (ACU193), currently in Phase 2 clinical trials [11] - The company collaborates with JCR Pharmaceuticals to advance its EBD therapy, leveraging proprietary drug delivery systems [11][12]

Company Overview - Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment [3] - The company is headquartered in Newton, Massachusetts [3] Product Development - Acumen is advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody, currently in a Phase 2 clinical trial (ALTITUDE-AD) for early symptomatic Alzheimer's disease patients [3] - The company reported positive results from its Phase 1 trial (INTERCEPT-AD) [3] - Acumen is also exploring a subcutaneous formulation of sabirnetug using Halozyme's ENHANZE® drug delivery technology [3] - Additionally, Acumen is collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer's disease utilizing a transferrin-receptor-targeting technology [3] Upcoming Events - Management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on March 18, 2026, at 11:00 a.m. ET [1] - The live webcast will be accessible under the Investors tab on the company's website and archived for 90 days [2]

Core Viewpoint - Acumen Pharmaceuticals is advancing its research on sabirnetug, a novel therapeutic targeting soluble amyloid beta oligomers for Alzheimer's disease, with new data to be presented at the upcoming AD/PD conference [1][2]. Group 1: Conference Presentations - Acumen will present one oral and two poster presentations at the International Conference on Alzheimer's and Parkinson's Diseases from March 17-21, 2026, in Copenhagen [1]. - The oral presentation will focus on enhanced brain delivery of sabirnetug in a mouse model of Alzheimer's disease [3]. - The poster presentations will cover biomarker treatment responses and the development of novel antibodies targeting amyloid beta oligomers [4]. Group 2: Research and Development - The oral presentation on enhanced brain delivery is part of a collaboration with JCR Pharmaceuticals, aiming to improve drug delivery to the brain and develop more effective treatment options for Alzheimer's disease [4]. - Sabirnetug (ACU193) is a humanized monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers, which are believed to be a significant factor in the neurodegenerative process of Alzheimer's disease [6]. - The ongoing Phase 2 clinical trial, ALTITUDE-AD, involves 542 participants and aims to evaluate the efficacy and safety of sabirnetug in slowing cognitive decline in early Alzheimer's disease [7]. Group 3: Company Overview - Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for Alzheimer's disease, leveraging its expertise in amyloid beta oligomers [8]. - The company is also exploring a subcutaneous formulation of sabirnetug using Halozyme's ENHANZE drug delivery technology [8]. - Acumen's scientific founders have pioneered research on amyloid beta oligomers, which are increasingly recognized as early triggers of Alzheimer's pathology [8].

Group 1: Stock Performance - Several healthcare and biotech stocks experienced significant gains in after-hours trading, with movements largely occurring without specific company news [1][2][3][4] - Acumen Pharmaceuticals, Inc. (ABOS) rose by 8.09% to close at $2.94, adding $0.22 to its share price [1] - Fulgent Genetics, Inc. (FLGT) increased by 5.98% to $28.90, gaining $1.63 in extended trading [1] - Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23, up $0.11 after hours [1] - Coeptis Therapeutics Holdings, Inc. (COEP) finished up 4.14% at $13.85, a gain of $0.55 [2] - Jin Medical International Ltd. (ZJYL) saw an increase of 4.04% to $0.16, up $0.0061 [2] - Alignment Healthcare, Inc. (ALHC) gained 5.92% to $22.20, adding $1.24 in after-hours trading [2] - Orthofix Medical Inc. (OFIX) rose 4.58% to $13.94, up $0.61 [3] - Alto Neuroscience, Inc. (ANRO) advanced 4.52% to $17.57, gaining $0.76 [3] - Immix Biopharma, Inc. (IMMX) increased by 3.87% to $6.17, adding $0.23 [3] - Amneal Pharmaceuticals, Inc. (AMRX) rose 3.76% to $14.35, up $0.52, and is set to replace TTM Technologies in the S&P SmallCap 600 index [3] - Tyra Biosciences, Inc. (TYRA) gained 3.76% to $32.58, adding $1.18 in extended trading [4]

Company Overview - Acumen Pharmaceuticals is a micro-cap biotech company focused on developing treatments for Alzheimer's disease, aiming to help patients "hold on to their moments" [1] - The company is addressing a significant market opportunity, with over 7 million people in the U.S. currently living with Alzheimer's, projected to rise to nearly 13 million by 2050 [1] Product Development - Acumen's lead drug candidate, sabirnetug, is a humanized monoclonal antibody targeting toxic amyloid-beta oligomers (AβOs), which are believed to contribute to synaptic dysfunction and neurodegeneration in Alzheimer's [7][8] - In its Phase 1 clinical trial (INTERCEPT-AD), sabirnetug demonstrated a favorable safety profile and positive biomarker effects, including reductions in amyloid plaque measures [9] - The FDA granted Fast Track designation for sabirnetug, facilitating its development for early Alzheimer's treatment [9] Clinical Trials and Future Plans - Acumen has initiated the Phase 2 ALTITUDE-AD trial to evaluate sabirnetug's ability to slow cognitive decline in early Alzheimer's patients, with topline results expected in late 2026 [10] - The company is also developing a next-generation strategy to enhance antibody delivery to the brain through a collaboration with JCR Pharmaceuticals, aiming for non-clinical data in early 2026 [12] Market Sentiment and Analyst Ratings - Analysts express optimism about Acumen's prospects, with Stifel's analyst Paul Matteis rating ABOS a Buy and setting a price target of $10, indicating a potential upside of 405% [15] - The stock has a Strong Buy consensus rating from Wall Street, with an average target price suggesting a 223% gain over the next year [15] Industry Context - The biotech sector is recovering from a cyclical trough, with improving macro conditions, increased FDA approvals, and rising investor confidence expected to drive strong performance in 2026 [3][4] - Biotech stocks are often influenced by catalysts such as clinical trial data and regulatory decisions, making careful stock selection crucial [5]

Summary of Key Points from the Conference Call Industry Overview - **Industry**: US Biopharmaceuticals - **Performance**: Biopharma ended 2025 positively with NBI up 32% and DRG up 21%, outperforming SPX at 17% [1] - **Outlook for 2026**: Optimism exists despite macro concerns like inflation and tariffs, with easing drug pricing worries, increased M&A activity, new product cycles, and modest expectations positioning the sector favorably [1] Core Insights and Arguments - **Valuation**: Biotech/Pharma P/E multiples are around 19x, which is lower compared to Financials at 18x and Utilities at 20x, indicating potential undervaluation [1] - **Catalysts**: Companies like Insmed (+152%), BridgeBio (+179%), and Travere (+119%) have shown strong performance driven by value-driving catalysts [1] Company-Specific Highlights Insmed - **Performance**: Insmed was a top performer in 2025, driven by Brinsupri's launch and TPIP's phase 2 results [2] - **2026 Outlook**: Continued upside is expected as Brinsupri's uptake alleviates skepticism over the $5B NCFB opportunity [2] BridgeBio - **Focus for 2026**: The debate will center around Attruby, with positive channel checks suggesting potential for accelerated sales [2] - **Key Data**: Anticipation for PROPEL3 readout in January, which could significantly impact the stock [10] Travere - **Performance**: Outperformance in 2025 attributed to commercial success in IgAN [3] - **Approval Outlook**: Filspari's potential approval for FSGS is a major debate, with FDA signals indicating a favorable outlook [9] Cytokinetics - **Market Entry**: Myqorzo's approval for oHCM is expected to face challenges in market execution against established competitors [15][40] - **Upcoming Data**: ACACIA readout in 2Q26 is crucial for assessing the drug's competitive position [19] Tyra - **Expansion**: Tyra is expanding dabogratinib's development into LG-UTUC, which could offer greater regulatory flexibility and market opportunity [43] - **Market Potential**: Management believes an oral option could be a game changer in a relatively underserved market [43] Acumen - **Pipeline Development**: Acumen's EBD program is expected to provide optionality, with initial non-clinical data anticipated early in 2026 [13] - **Key Event**: ALTITUDE-AD is a defining event for Acumen, with expectations for significant data to outperform competitors [33] Additional Important Insights - **M&A Activity**: The biopharma sector is seeing increased M&A activity as companies prepare for patent expirations [1] - **Regulatory Environment**: The FDA's involvement in various drug approvals and feedback mechanisms is crucial for shaping market expectations [9][10] - **Investor Sentiment**: There remains a cautious sentiment among investors, particularly regarding the approval of new drugs and their market uptake [9][19] This summary encapsulates the key points from the conference call, highlighting the overall industry outlook, company-specific developments, and critical upcoming events that could influence market dynamics in the biopharmaceutical sector.

Core Insights - Several biotechnology and pharmaceutical companies experienced significant stock price increases in after-hours trading due to clinical trial updates, regulatory advancements, and investor anticipation for upcoming data releases [1] Company Updates - Alumis Inc. (ALMS) saw a surge of 17.33% to $9.75, gaining $1.44 after announcing that topline data from its Phase 3 ONWARD clinical program for envudeucitinib in moderate-to-severe plaque psoriasis will be reported on January 6, 2026, along with a conference call to discuss the results [2] - Genelux Corp. (GNLX) climbed 10.92% to $3.86, up $0.38, following interim results from ongoing trials evaluating Olvi-Vec in patients with progressive small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) [3] - Bright Minds Biosciences Inc. (DRUG) rose 8.42% to $86.75, gaining $6.74, and announced a conference call on January 6, 2026, to report topline results from its Phase 2 trial of BMB-101 in patients with drug-resistant Absence Seizures [4] - Context Therapeutics Inc. (CNTX) shares increased by 8.36% to $1.68, adding $0.13, despite no specific news released [4] - BioAtla, Inc. (BCAB) gained 3.95% to $0.44, up $0.017, after announcing a special purpose vehicle transaction to advance ozuriftamab vedotin in a Phase 3 study for oropharyngeal squamous cell carcinoma, receiving $5 million in initial funding [5] - Femasys Inc. (FEMY) added 7.09% to $0.6223, up $0.04, with no new updates reported [5] - Acumen Pharmaceuticals, Inc. (ABOS) jumped 11.62% to $2.21, gaining $0.23, also without new corporate updates [6] - Alpha Tau Medical Ltd. (DRTS) rose 5.36% to $5.50, up $0.28, after submitting the first module of its pre-market approval application to the FDA for Alpha DaRT in treating recurrent cutaneous squamous cell carcinoma [7]